Pemetrexed for Injection 100mg/Vial
Somerset Therapeutics recalls Pemetrexed for Injection 100mg/Vial due to cGMP deviations.
If you have the affected Pemetrexed for Injection 100mg/Vial, stop using it immediately and contact your healthcare provider or the company for further instructions.
Why it was recalled
Somerset Therapeutics is recalling Pemetrexed for Injection 100mg/Vial, a chemotherapy drug, due to cGMP deviations. The recall affects single-dose vials supplied in cartons of one 10 mL vial for intravenous use.
Is mine affected?
Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
| Product | Lot code | Strength | NDC / UPC | Recall # |
|---|---|---|---|---|
| Pemetrexed for Injection | RPTH0125A, 2028 | 500 mg | NDC 70069-0835-01 | D-0672-2026 |
| Bortezomib for Injection | RBIH0125A, 2028 | 3.5 mg | NDC 70069-0836-01 | D-0673-2026 |
| Azacitidine for Injection | RAZM0425A, 2027 | 100 mg | NDC 70069-0857-01 | D-0674-2026 |
| Pemetrexed for Injection | RPTL0325A, 2027 | 100 mg | NDC 70069-0834-01 | D-0671-2026 |
Where it was sold
Distributed nationwide.
Timeline
- Firm initiated recall
- Publicly announced
- Listed on Recall Canary
- Summary updated
Official source
Other Manufacturing Deviation recalls
Editorial summary by Recall Canary · summary updated 2026-09-03 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification